Results 11 to 20 of about 178 (88)

Current aspects of the treatment of different types of vertigo

Медицинский совет, 2021
Dizziness is one of the most frequent complaints of patients in daily clinical practice. The prevalence of vertigo increases significantly in older patients.
L. M. Antonenko
doaj   +1 more source

Pharmacokinetics and Dose Proportionality of Betahistine in Healthy Individuals

Scientia Pharmaceutica, 2020
Betahistine dihydrochloride is widely used to reduce the severity and frequency of vertigo attacks associated with Ménière’s disease.
Duaa J. Al-Tamimi, Afaq M. Ammoo, Mays E. Alani, Jaafar J. Ibraheem   +3 more
doaj   +1 more source

Conductometric determination of Betahistine dihydrochloride and Heptaminol hydrochloride using silver nitrate

Zagazig Journal of Pharmaceutical Sciences, 2019
A simple, precise and cost effective conductometric method was developed for determination of betahistine dihydrochloride and heptaminol hydrochloride in pure form and pharmaceutical formulations. The method is based on the precipitation of chloride ions
Magda M Ayad , Mervat M Hosny , Omar M Elabassy , Fathalla Belal   +3 more
doaj   +1 more source

Vestibular vertigo treatment in a polymorbid patient

Неврология, нейропсихиатрия, психосоматика, 2018
Many physicians have difficulty managing patients with vertigo. Incorrect routine diagnoses are frequently made in patients with peripheral vestibulopathy, which makes therapy fail.
O. V. Kosivtsova, S. A. Yavorskaya, T. G. Fateeva   +2 more
doaj   +1 more source

EFFECTS OF BETAHISTINE DIHYDROCHLORIDE AS ADJUVANT TO ENALAPRIL THERAPY OF PATIENTS WITH CHRONIC HEART FAILURE CLASS II-II (NYHA) SUFFERING FROM GIDDINESS

Рациональная фармакотерапия в кардиологии, 2016
Aim. To study adjuvant effect of betahistine dihydrochloride to ACE inhibitors in patients with chronic heart failure (CHF) class II-III suffering from giddiness.Material and methods.
S. Y. Martsevich, J. V. Lukina, V. V. Yakusevich, D. A. Anichkov, A. D. Deev, O. V. Lerman, S. N. Tolpygina, N. A. Dmitrieva, A. A. Serazhim, M. A. Maksimova, V. P. Voronina, E. V. Shilova, G. F. Andreeva, A. V. Zaharova, I. V. Novikov, А. А. Platonova, Т. А. Kazakovtseva, T. V. Babkova, L. P. Volhonskaya   +18 more
doaj   +1 more source

Betahistine dihydrochloride quantitative determination in dosage forms by the reaction with sodium 1,2-napthoquinone-4-sulphonate

Zaporožskij Medicinskij Žurnal, 2018
, Objectives. Spectrophotometric method is one of the most convenient methods in pharmaceutical analysis, as it is sensitive, precise and cost effective.
A.O. Donchenko, S. O. Vasyuk
doaj   +1 more source

DIZZINESS OF ISCHEMIC GENESIS: DESCRIPTION OF VESTIBULAR DISORDERS AND POSSIBILITY OF THERAPY

Рациональная фармакотерапия в кардиологии, 2015
Aim. To reveal the peculiarities of peripheral and central vestibular disorders in patients with mild dizziness in initial and reversible cerebrovascular diseases and estimate the efficacy of dizziness therapy with betahistine dihydrochloride (Betaserc ...
N. S. Alekseeva
doaj   +3 more sources

Treatment of vertigo in elderly patients with chronic cerebrovascular disease

Неврология, нейропсихиатрия, психосоматика, 2018
Dizziness can be caused by different problems in elderly patients; the possibilities of drug therapy are limited; betahistine dihydrochloride is most commonly used.Objective: to investigate the efficiency and safety of combination therapy with mexidol ...
S. N. Duma
doaj   +1 more source

Diagnosis and treatment of dizziness in outpatient practice

Неврология, нейропсихиатрия, психосоматика, 2015
Objective: to study the causes of dizziness and instability in patients during an outpatient specialized appointment and to analyze and improve typical management tactics for these patients. Patients and methods.
L. M. Antonenko, N. V. Bestuzheva, V. A.
 Parfenov   +2 more
doaj   +1 more source

Formulation And Performance Evaluation Of Betahistine Dihydrochloride Microspheres As Sustained Release Systems

Folia Medica, 2014
Бетагистин дигидрохлорид представляет собой гистаминовый аналог, широко применяемый для облегчения симптомов, сопутствующих синдром Мениера. По данным фармакокинетических исследований бетагистамин имеет краткую плазменную полужизнь - 3.4 ч.
Pilicheva Bissera A., Kassarova Margarita I., Zagorchev Plamen I., Uzunova Yordanka I.   +3 more
doaj   +1 more source